<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941028-2-00189</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <TABLE>  <!-- PJG tableformat 8,L2,i1,xs27,r50,xs36,xs48,xs45,xs36,r60,xl50 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=4 --> Table S2&hyph;2._Regimen Options for the Treatment of Tuberculosis (TB) in Children and Adults <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Option <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Indication <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Total duration of therapy <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Initial treatment phase <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2Drugs* <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2Interval and duration <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Continuation treatment phase <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2Drugs* <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2Interval and duration <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Comments <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=4 --> 1 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Pulmonary and extrapulmonary TB in adults and children <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 6 mos <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> INH <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lRIF <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lPZA <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lEMB or SM <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Daily for 8 wks <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> INH <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lRIF <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Daily or two or three times wkly <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=5 f=1 -->  <!-- PJG 0036 unknown -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 -->  for 16 wks <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=5 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> &bull;EMB or SM should be continued until susceptibility to INH and RIF is demonstrated. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> &bull;In areas where primary INH resistance is &lt;4%, EMB or SM may not be necessary for patients with no individual risk factors for drug resistance. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Pulmonary and extrapulmonary TB in adults and children <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 6 mos <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> INH <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lRIF <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lPZA <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lEMB or SM <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Daily for 2 wks, then two times wkly <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=5 f=1 -->  <!-- PJG 0036 unknown -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 -->  for 6 wks <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> INH <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lRIF <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Two times wkly <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=5 f=1 -->  <!-- PJG 0036 unknown -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 -->  for 16 wks <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=5 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> &bull;Regimen should be directly observed. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> &bull;After the initial phase, EMB or SM should be continued until susceptibility to INH and RIF is demonstrated, unless drug resistance is unlikely. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Pulmonary and extrapulmonary TB in adults and children <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 6 mos <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> INH <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lRIF <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lPZA <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lEMB or SM <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=40 g=1 f=1 --> (2)3 times wkly <!-- PJG /ITAG -->  <!-- PJG ITAG l=40 g=5 f=1 -->  <!-- PJG 0036 unknown -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=40 g=1 f=1 -->  for 6 mos <!-- PJG /ITAG -->  <!-- PJG ITAG l=40 g=5 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=40 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> &bull;Regimen should be directly observed. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> &bull;Continue all four drugs for 6 mos. <!-- PJG /ITAG -->  <!-- PJG ITAG l=40 g=5 f=1 --> &para; <!-- PJG /ITAG -->  <!-- PJG ITAG l=40 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> &bull;This regimen has been shown to be effective for INH-resistant TB. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> 4 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Smear- and culture-negative pulmonary TB in adults <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 4 mos <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> INH <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lRIF <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lPZA <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lEMB or SM <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Follow option 1, 2, or 3 for 8 wks <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> INH <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lRIF <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lPZA <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lEMB or SM <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Daily or two or three times wkly <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=5 f=1 -->  <!-- PJG 0036 unknown -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 -->  for 8 wks <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> &bull;Continue all four drugs for 4 mos. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> &bull;If drug resistance is unlikely (primary INH resistance &lt;4% and patient has no individual risk factors for drug resistance), EMB or SM may not be necessary and PZA may be discontinued after 2 mos. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 5 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Pulmonary and extrapulmonary TB in adults and children when PZA is contraindicated <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> 9 mos <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> INH <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lRIF <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lEMB or  <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lSM** <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Daily for 8 wks <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> INH <!-- PJG 007 0120 intable -->  <!-- PJG 007 0170 intable --> lRIF <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Daily or two times wkly <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=5 f=1 -->  <!-- PJG 0036 unknown -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 -->  for 24 wks <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=5 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> &bull;EMB or SM should be continued until susceptibility to INH and RIF is demonstrated. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0120 intable --> &bull;In areas where primary INH resistance is &lt;4%, EMB or SM may not be necessary for patients with no individual risk factors for drug resistance. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0146 intable --> *EMB=ethambutol; INH=isoniazid; PZA=pyrazinamide; RIF=rifampin; SM=streptomycin. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0146 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=5 f=1 -->  <!-- PJG 0036 unknown -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> All regimens administered intermittently should be directly observed. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0146 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=5 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> For infants and children with miliary TB, bone and joint TB, or TB meningitis, treatment should last at least 12 months. For adults with these forms of extrapulmonary TB, response to therapy should be monitored closely. If response is slow or suboptimal, treatment may be prolonged on a case-by-case basis. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0146 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=5 f=1 --> &para; <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> Some evidence suggests that SM may be discontinued after 4 months if the isolate is susceptible to all drugs. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0146 intable --> **Avoid treating pregnant women with SM because of the risk of ototoxicity to the fetus. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0146 intable -->  <!-- PJG ITAG l=01 g=1 f=2 --> Note:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=1 --> For all patients, if drug-susceptibility results show resistance to any of the first-line drugs, or if the patient remains symptomatic or smear- or culture-positive after 3 months, consult a TB medical expert. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <TABLE>  <!-- PJG tableformat 7,L2,i1,s50,r50,r50,r50,r50,r50,r50 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=4 --> Table  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 --> S2&hyph;3._ <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=4 --> Dosage Recommendations for the Initial Treatment of Tuberculosis in Children* and Adults <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Drug <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Dosage schedule <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2Daily dose (maximum dose) <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 3Children <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 3Adults <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2Two doses per week (maximum dose) <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 3Children <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 3Adults <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2Three doses per week (maximum dose) <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 3Children <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 3Adults <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=4 --> Isoniazid <!-- PJG 007 0104 intable --> 10&hyph;20 mg/kg (300 mg) <!-- PJG 007 0104 intable --> 5 mg/kg (300 mg) <!-- PJG 007 0104 intable --> 20&hyph;40 mg/kg (900 mg) <!-- PJG 007 0104 intable --> 15 mg/kg (900 mg)  <!-- PJG 007 0104 intable --> 20&hyph;40 mg/kg (900 mg) <!-- PJG 007 0104 intable --> 15 mg/kg) (900 mg) <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Rifampin <!-- PJG 007 0104 intable --> 10&hyph;20 mg/kg (600 mg) <!-- PJG 007 0104 intable --> 10 mg/kg (600 mg) <!-- PJG 007 0104 intable --> 10&hyph;20 mg/kg (600 mg) <!-- PJG 007 0104 intable --> 10 mg/kg (600 mg) <!-- PJG 007 0104 intable --> 10&hyph;20 mg/kg (600 mg) <!-- PJG 007 0104 intable --> 10 mg/kg (600 mg) <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Pyrazinamide <!-- PJG 007 0104 intable --> 15&hyph;30 mg/kg (2 gm) <!-- PJG 007 0104 intable --> 15&hyph;30 mg/kg (2 gm) <!-- PJG 007 0104 intable --> 50&hyph;70 mg/kg (4 gm) <!-- PJG 007 0104 intable --> 50&hyph;70 mg/kg (4 gm) <!-- PJG 007 0104 intable --> 50&hyph;70 mg/kg (3 gm) <!-- PJG 007 0104 intable --> 50&hyph;70 mg/kg (3 gm) <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Ethambutol <!-- PJG 007 0104 intable --> 15&hyph;25 mg/kg <!-- PJG 007 0104 intable --> 15&hyph;25 mg/kg  <!-- PJG 007 0104 intable --> 50 mg/kg  <!-- PJG 007 0104 intable --> 50 mg/kg  <!-- PJG 007 0104 intable --> 25&hyph;40 mg/kg  <!-- PJG 007 0104 intable --> 25&hyph;30 mg/kg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Streptomycin <!-- PJG 007 0104 intable --> 20&hyph;40 mg/kg (1 gm) <!-- PJG 007 0104 intable --> 15 mg/kg (1 gm) <!-- PJG 007 0104 intable --> 20&hyph;40 mg/kg (1.5 gm) <!-- PJG 007 0104 intable --> 20&hyph;40 mg/kg (1.5 gm) <!-- PJG 007 0104 intable --> 20&hyph;40 mg/kg (1.5 gm) <!-- PJG 007 0104 intable --> 20&hyph;40 mg/kg (1.5 gm) <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0146 intable --> *Persons &lt;12 years of age. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  </TABLE>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            